SCHEMBL20090128

SCHEMBL20090128

O=P(c1ccccc1)(c1ccccc1)c1ccc(-c2ccc(-c3ccc4c(c3)c3ccc5ccccc5c3c3nc5ccccc5n43)cc2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.38
HPGD P15428 5/20 0.38
KDM4E B2RXH2 5/20 0.38
KMT2A Q03164 6/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
PTGES O14684 1/20 0.37
MAPT P10636 5/20 0.36
POLB P06746 2/20 0.36
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36
HSD17B10 Q99714 1/20 0.36
MEN1 O00255 4/20 0.36
CAMKK1 Q8N5S9 2/20 0.36
CAMKK2 Q96RR4 2/20 0.36
CYP1A2 P05177 2/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CASP1 P29466 1/20 0.36
CYP2C19 P33261 1/20 0.36
CASP7 P55210 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14644288 1.00 ALDH1A1 (0.38) ALDH1A1HPGDKDM4EKMT2ASMN1; SMN2
SCHEMBL19960412 0.96 HPGD (0.36) ALDH1A1HPGDKDM4EKMT2ASMN1; SMN2
SCHEMBL19960050 0.94 KDM4E (0.38) ALDH1A1HPGDKDM4EKMT2ASMN1; SMN2
SCHEMBL20090127 0.93 ALDH1A1 (0.41) ALDH1A1HPGDKDM4EKMT2ASMN1; SMN2
SCHEMBL14644211 0.93 ALDH1A1 (0.41) ALDH1A1HPGDKDM4EKMT2ASMN1; SMN2
SCHEMBL14644067 0.92 KMT2A (0.43) ALDH1A1HPGDKDM4EKMT2ASMN1; SMN2
SCHEMBL20090134 0.92 KMT2A (0.43) ALDH1A1HPGDKDM4EKMT2ASMN1; SMN2
SCHEMBL19929016 0.90 ALDH1A1 (0.36) ALDH1A1HPGDKDM4EKMT2ASMN1; SMN2
SCHEMBL14643474 0.90 HPGD (0.47) ALDH1A1HPGDKDM4EKMT2ASMN1; SMN2
SCHEMBL19960051 0.89 KDM4E (0.39) ALDH1A1HPGDKDM4EKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3266780-B1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME LG CHEMICAL LTD (KR) 2020-02-19 EP disclosed
US-10355225-B2 Heterocyclic compound and organic light emitting element comprising same LG CHEM, LTD. (KR) 2019-07-16 US disclosed
US-20180114923-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME LG CHEM, LTD. (KR) 2018-04-26 US disclosed
US-20180114923-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME LG CHEM, LTD. (KR) 2018-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180114923-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME CRY1, CRY2, PER2 ALDH1A1 750/4885HPGD 2982/4885KDM4E 1997/4885
US-10355225-B2 Heterocyclic compound and organic light emitting element comprising same CRY1, CRY2, PER2 ALDH1A1 750/4885HPGD 2982/4885KDM4E 1997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.